Cyclops®

Protected: CYCLOPS® Dry Powder Inhaler Now Available Nationwide in the Netherlands Thanks to Agreement Between Fagron and PureIMS

Month: September 2024

Protected: CYCLOPS® Dry Powder Inhaler Now Available Nationwide in the Netherlands Thanks to Agreement Between Fagron and PureIMS

Protected: CYCLOPS® Dry Powder Inhaler Now Available Nationwide in the Netherlands Thanks to Agreement Between Fagron and PureIMS

There is no excerpt because this is a protected post.

International Congress of Parkinson’s Disease and Movement Disorders 2024 – poster on Levodopa Cyclops®

International Congress of Parkinson’s Disease and Movement Disorders 2024 – poster on Levodopa Cyclops®

Please check out our latest poster (#708) presenting clinical study results of a head-to-head comparison between Levodopa Cyclops® and Inbrija®. Highlights are: Levodopa Cyclops® is safe and very well tolerated (no cough). Levodopa absorption from Cyclops® is comparable to Inbrija®, thereby, fulfilling the bioequivalence criteria. Results enable abbreviated registration routes with a limited – PK-only […]